In patients with advanced HCC, the combination of atezolizumab (an anti-PD-L1 monoclonal antibody) and bevacizumab (an anti-VEGF-A monoclonal antibody) has demonstrated better efficacy than sorafenib, establishing a new first-line treatment standard with a median OS of 19 months, marking a significant advancement in the treatment of HCC [144]. Here, VEGFA is linked to hepatocellular carcinoma.